Amryt Pharma Loss Widens After Costs Rise As Lojuxta Boosts Revenue
April 17 2018 - 7:26AM
Alliance News
News) - Amryt
Pharma PLC said Tuesday its 2017 loss widened on higher
administrative and research & development costs ...
Subscribe now to see this Premium News
article from
Alliance News Professional covers every UK
stock in your portfolio. It goes beyond regulatory news and free
web services to give your investment decisions an edge over the
crowd.
- In The
Know - Management and analyst comments that go beyond company
announcements.
- Flash headlines on all 2,400 London-listed companies before the
news hits the open web.
- Broker Ratings - The
earliest tip-offs, many before the market opens.
- Economic data and central bank flashes from UK, US and
eurozone.
- Taking
AIM - Up to the minute market commentary on AIM stocks.
- Over 500 news items per trading day for just £39.60 per month,
and cancel at any time.
Call us on +44 (0) 203 8794 460 to get
started.
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Amryt Pharma Plc (London Stock Exchange): 0 recent articles
More News Articles